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Abstract
Literature regarding acute human toxicity of thiopurines is limited to a handful of case reports. Our objectives were to
describe all cases of overdose with thiopurines reported to the Swiss Toxicological Information Centre between 1995–2013.
A retrospective analysis was performed to determine circumstances, magnitude, management and outcome of overdose
with these substances. A total of 40 cases (14 paediatric) were reported (azathioprine, n = 35; 6-mercaptopurine, n = 5). Of
these, 25 were with suicidal intent, 12 were accidental and 3 were iatrogenic errors. The magnitude of overdose ranged
from 1.5 to 43 (median 8) times the usual dose in adults. Twelve cases (30%) had attributable symptoms. The majority of
these were minor and included gastrointestinal complaints and liver function test and blood count abnormalities.
Symptoms were experienced by patients who took at least 1.5-times their usual daily thiopurine dose. Overdoses over two
or more consecutive days, even if of modest size, were less well tolerated. One case of azathioprine and allopurinol co-
ingestion over consecutive days led to agranulocytosis. Decontamination measures were undertaken in 11 cases (10
activated charcoal, 1 gastric lavage) and these developed fewer symptoms than untreated patients. This study shows that
acute overdoses with thiopurines have a favourable outcome in the majority of cases and provides preliminary evidence
that gastrointestinal decontamination with activated charcoal may reduce symptom development after overdose of these
substances if patients present to medical services soon after ingestion.
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Introduction
Thiopurines are immunosuppressant drugs used in the treat-
ment of autoimmune conditions and acute leukaemias as well as in
the prevention of acute rejection after solid organ transplantation.
Azathioprine (AZA), 6-mercaptopurine (6-MP) and thioguanine
are the thiopurines currently in use and have been licensed in
Switzerland for 48, 58 and 40 years, respectively. AZA is a
precursor of 6-MP which in turn is a precursor of thioguanine.
Being purine antimetabolites, thiopurines prevent normal cell
development and division of rapidly expanding cell lines such as
haematological cell lines which leads to their desired immunosup-
pressive effects as well as to toxicity. Patients taking these agents or
their household contacts may be intentionally or accidentally
exposed to overdose. Despite several decades of experience in
using thiopurines and a good knowledge about long-term toxicity,
the published information regarding acute toxicity in overdoses
only consists of a small number of case reports from different
centres [1–6].
Gastrointestinal symptoms such as nausea, vomiting, abdominal
pain and diarrhoea appear to be the commonest early initial
features of acute toxicity, followed by subsequent reversible liver
function test and haematological abnormalities, however the
collective experience is limited. Furthermore little is known about
the circumstances and optimal management of thiopurine
overdose – a condition for which no specific antidotes are
available. The purpose of this study was to investigate the
circumstances, management and outcomes of overdoses with
thiopurines using data reported to a single national poison centre
during an 18-year period.
Materials and Methods
Study design
A specific ethics approval was not required for this observational
study due to the nature of the study design according to the
regulations of the cantonal ethics committee Zurich, Switzerland
(www.kek.zh.ch/) which also state that anonymised data generated
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during patient care can be used retrospectively for research
purposes without obtaining written consent. We performed a
retrospective review of all acute overdoses involving thiopurines in
adults and children (,16 years) either alone or in combination
with other drugs that had been reported to the Swiss Toxicological
Information Centre (STIC) between April 1995 and August 2013
(for further details, please see the online Supporting Information
Methods S1). Cases are assigned an internal identification number
and neither the patients nor the reporting professionals could be
identified by the investigators.
Circumstances and symptoms of overdose
The circumstances of overdose were categorised as ‘suicidal’ for
cases of intentional overdose, ‘domestic’ for cases of accidental
overdose in the home and ‘iatrogenic’ for those due to a
prescribing or administration error in hospital.
The severity of symptoms were graded in accordance with the
Poisoning Severity Score (PSS) as ‘minor’, for mild, transient and
spontaneously resolving symptoms/signs; ‘moderate’, if at least
one pronounced or prolonged symptom/sign was recorded;
‘severe’, if at least one severe or life-threatening symptom/sign
was observed, or ‘fatal’, if the overdose was the recorded cause of
death [7].
Cases were assessed for association between symptoms and the
immunosuppressant overdose by an expert panel including a
senior clinical pharmacologist and a senior clinical toxicologist,
both with additional qualifications in general internal medicine,
using the World Health Organisation Uppsala Monitoring Centre
(WHO-UMC) standardised case causality assessment criteria
originally developed for the assessment of adverse drug reactions
[8]. Co-morbidities, co-ingestion of other medication (in patients
with multiple drug overdose or taking other drugs in the
therapeutic dose range) and the magnitude of overdose were
taken into consideration. Associations were classified as ‘certain’,
‘likely’, ‘possible’ and ‘unlikely’ (Table S1).
Statistical analyses
Descriptive statistics were used to analyse grouped data.
Overdoses in mg/kg were compared with usual therapeutic doses
by determining the multiple of the subject’s usual therapeutic dose
(dose ingested/usual dose). In subjects who did not normally
receive a thiopurine or in cases where the usual maintenance dose
was not known, the magnitude of overdose above the maximum
licensed dose was determined. In Switzerland the maximum
licensed doses for oral AZA is 5 mg/kg/day (adults and children),
and for oral 6-MP 2.5 mg/kg/day (adults and children) [9–10].
Missing data regarding patient weight was computed as detailed in
the online Supporting Information (Methods S1).
Results
Cases
There were a total of 152762 reports to the STIC of confirmed
or suspected overdose with any substance by healthcare profes-
sionals during the study period. Of these, 35 were with AZA and
five with 6-MP. There were no overdoses with thioguanine.
Thirty-five cases were reported by hospital doctors and five by
other doctors. Demographic characteristics, circumstances of
overdose, the magnitude of overdose and the availability of
follow-up data are given in Table 1. Adults and children are
presented separately. Table S2 shows the details of each individual
case. Nine of the total 12 accidental domestic overdoses were in
children under the age of four living with parents or siblings
undergoing treatment with thiopurines.
Table S3 shows the magnitude of overdose in relation to the
patient’s usual maintenance dose or - for treatment-naı¨ve
individuals - in relation to the maximum licensed dose for each
case. Four of the exposures (all with AZA) were retrospectively
found to be less than the maximum licensed dose and were all
cases of accidental ingestion by children. These cases were
considered ‘accidental exposures within the therapeutic range’
rather than ‘overdose’ and were not included in the analysis of
symptom development in order to accurately reflect the effect of
true overdose.
There were three instances in which patients were exposed to
‘repeated overdoses’. Patient 29 had been co-treated with
allopurinol for a number of days, patient 34 took an overdose of
the same size on the two consecutive evenings prior to seeking
medical attention and patient 35 unintentionally took double his
prescribed dose for three days prior to presentation.
Outcomes
The outcomes of overdose are given in detail in Table S3. None
of the 6-MP overdoses caused symptoms. AZA was judged to have
caused or contributed to symptoms or abnormal clinical findings
in 12 of the 31 true overdose cases. The four children not usually
taking AZA who were exposed to it in the therapeutic range did
not develop symptoms. Symptoms attributable to AZA overdose
were nausea and vomiting (n = 5), abdominal pain (n = 3),
palpitations or sinus tachycardia (n = 2), headache (n = 2) and
dyspnoea (n = 1). Laboratory findings attributable to thiopurine
ingestion were increased liver enzymes (n = 3) and changes in
blood count (n = 2). The symptom severities were classified as
follows: 14 minor, three moderate and one severe. The severe case
(patient 29) had undergone co-therapy with AZA and allopurinol
prior to presenting with sepsis secondary to agranulocytosis. The
duration of the co-therapy and the doses in this case are unknown.
The three cases in which AZA was taken in overdose over two or
more days (in one case in the context of the above-mentioned
drug-drug interaction) all developed symptoms or signs attribut-
able to AZA. No patients who ingested 1.5 times or less of their
usual or the maximum licensed AZA dose developed symptoms.
Patients who developed symptoms after overdose on a single
occasion had been exposed to a mean of 14.1611 times their usual
or maximum licensed dose compared to asymptomatic patients
who were exposed to 7.968.8 times their usual or maximum
licensed dose.
Management
In total, 4 patients were discharged immediately after initial
evaluation in the emergency room, 5 were admitted for brief
observation and discharged on the day of presentation, and 10
were admitted to acute medical wards. Hospitalisation status was
unknown in 21 patients. Of those hospitalised, median length of
stay was two days (range 1–11). Care was transferred from acute
medical to psychiatric in-patient services in 6 cases. Among the
subgroup of monointoxications for whom data were available, four
were discharged on the same day, one patient after three days, one
after more than eight days (exact figure unknown) and one after 11
days; all were asymptomatic.
The recommendation for use and subsequent use of decontam-
ination measures is shown in Table S3. In 11 (28%) cases measures
such as administration of activated charcoal (n = 9), induction of
vomiting by ipecac syrup and activated charcoal administration
(n = 1), or gastric lavage (n = 1) were performed. No decontam-
ination measures were undertaken in 14 (35%) patients and in 15
(38%) it is not known if any action was performed. Haemodialysis
was only proposed in patient 29 who had received AZA and
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allopurinol co-therapy. Gastrointestinal decontamination was
performed more often in paediatric patients: 8 underwent it, 1
did not, and data were unavailable for five. Among the adults,
these figures were 3, 13 and 10, respectively. Decontamination was
performed in 1 case of accidental exposure within the therapeutic
range and recommended in another case. Blood counts were
performed in 11 (28%) cases (median four days after overdose,
range 0.25–10 days) and liver function tests in 10 (25%) (median
four days after overdose, range 0.25–10 days).
Effect of decontamination
Fewer patients who received activated charcoal or underwent
gastric lavage after overdose developed symptoms compared to
patients in whom gastrointestinal decontamination was not
performed. Nine of ten (90%) patients who underwent gastroin-
testinal decontamination after overdose remained asymptomatic
compared to seven of the 14 (50%) who did not undergo
gastrointestinal decontamination. No patients with 6-MP overdose
developed symptoms, however follow-up was only one hour in the
cases who did not receive decontamination. The mean multiple
above patients’ usual dose or maximum licensed dose of
thiopurines were similar in the treated and untreated patients
(10.68612.63 and 10.42610.5 respectively) while the mean times
between overdose and presentation to medical services were
approximately 2.8 hours (median 1.5, range ,1–12 h) and
23 hours (median 2.25, range ,1–96 h) respectively. No adverse
effects resulting from treatment with activated charcoal or gastric
lavage were reported.
Discussion
This retrospective analysis of thiopurine overdoses reported to a
single national poison centre between 1995 and 2013 adds a
further 40 cases to the eight case reports currently published in the
medical literature [1–6]. A large dataset such as the one presented
here allows patterns, outcomes and management strategies of
thiopurine overdoses to be more comprehensively assessed.
Circumstances of overdose
The majority of overdoses in adult patients were with suicidal
intent (usually in conjunction with other medication), whereas
accidental overdoses were the most common among children. The
current literature includes four adult cases, none of which were
with suicidal intent and four paediatric cases [1–6]. Three of the
adult cases were iatrogenic where 6-MP had been dispensed
instead of propylthiouracil [3,6] and the remaining case was
accidental due to failure to understand the prescriber’s instructions
[1]. Among published cases in children, two were with suicidal
intent [2,5] and two were accidental ingestions by siblings of
children receiving 6-MP [4]. While the majority of adults who took
thiopurine overdoses with suicidal intent in the current series were
themselves patients suffering from a chronic disease requiring
immunosuppression, there were at least two cases where suicide
was attempted by taking an overdose of a household contact’s
medication. Similarly, nine of the 11 accidental ingestions in
children also involved a household contact’s medication as in the
two cases reported by Chow and colleagues [4]. Such cases further
emphasise the need to repeatedly instruct patients to keep
medicines out of reach of unintended recipients.
In contrast to the previously published literature about
thiopurine overdoses and our findings for calcineurin inhibitor
overdoses, where iatrogenic errors accounted for 38% and 46%
respectively of the reported cases [1–6,11], iatrogenic dosing errors
only accounted for 8% of the current series. This may be due to
the fact that the trade names for propylthiouracil and 6-MP in
Switzerland are PropycilH and Puri-NetholH respectively, which
Table 1. Demographic characteristics, circumstances, magnitude of overdose and follow-up data of the cases.
Adults Children
Number (%) 26 (65%) 14 (35%)
Azathioprine 26 (100%) 9 (64%)
6-mercaptopurine 0 5 (36%)
Male (%) 12 (46%) 9 (64%)
Body mass range (kg) (n for which data available) 50–80 (13) 11–48 (14)
Access to immunosuppression:
Condition requiring immunosuppression (%) 18 (69%) 3 (21%)
No underlying condition requiring immunosuppression (%) 1 (4%) 10 (72%)
Unknown 7 (27%) 1 (7%)
Circumstances of overdose
Suicidal intent 22 (85%) 3 (21%)
Domestic 1 (4%) 11 (79%)
Iatrogenic 3 (11%) 0
Overdose with more than one substance 20 (77%) 3 (21%)
Median overdose as a multiple of usual ingested dose or maximum
licensed dose (range), (number for which data available)
8 (1.5–49) (25) 3 (0.22–13) (14)
Median time (h) until contact with poisons information centre (range)
(number for which data available)
4 (,1–225) (23) ,1 (,1–8) (13)
Number of cases for whom follow-up available 14 7
Median follow-up time (range) (days) 4 (1–24) 5 (1–30)
Data was available for all cases unless otherwise specified.
doi:10.1371/journal.pone.0086390.t001
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are more markedly different than in the USA where the mix-up
errors occurred (PropylthiouracilH and PurinetholH respectively)
[3,6]. Furthermore, intravenous and liquid oral formulations,
which accounted for almost three quarters of the CNI iatrogenic
overdoses, are much less commonly used for the administration of
thiopurines.
Symptoms
Symptoms occurring during the first few hours after thiopurine
overdose were nausea, vomiting, abdominal pain, palpitations or
tachycardia, and headache. Other than tachycardia and palpita-
tions, these symptoms have been noted in other cases of overdose
[1,2] or are reported in the product information for AZA and 6-MP
[9,10]. AZA has been associated with bradycardia [12] but not with
tachycardia before. In the two cases of tachycardia we report,
despite there being a good temporal correlation between AZA
exposure and symptom development and no other concurrent drugs
taken in overdose, the tachycardia may have additionally been
caused by the circumstances of presentation (hospitalisation after a
suicide attempt). We therefore judged the association to be ‘possible’
in accordance with the WHO causality criteria.
The weight-adjusted exposures in the three patients who
developed blood count and/or liver function test changes and
for whom complete data were available were 180 mg/kg (patient
19), 33 mg/kg (patient 28) and 18.6 mg/kg (patient 1). All of these
overdoses were well below the median lethal dose (LD50) of AZA
in mice (2500 mg/kg) and rats (400 mg/kg) [13] which might
explain the paucity of severe symptoms seen in ours and the
reported cases. Due to packaging size, patients are unlikely to have
access to a dose which would cause severe toxicity if taken on a
single occasion. This is in contrast to other drugs commonly taken
in overdose such as acetaminophen, benzodiazepines and opiates.
Our findings and those previously published in the literature
suggest that single overdoses of thiopurines are generally well
tolerated [1,2,4,5]. Sustained overdoses over two or more days,
even if modest in size, however, are less well tolerated, as we found
in three cases and as is also reported in the literature [3,6]. This
discrepancy in findings between acute and sustained overdoses is
likely due to the relatively short half-lives of AZA and 6-MP (4.5
and 0.9 hours respectively), which means that nearly all of the
parent compound will have been eliminated approximately 23 and
5 hours respectively after overdose on a single occasion. The
development of severe symptoms after co-therapy with AZA and
allopurinol can be explained by the inhibition of xanthine oxidase
by allopurinol. This leads to reduced conversion of the active 6-
MP into the inactive 6-thiouric acid metabolite and consequently
to myelosuppression unless the thiopurine dose is reduced to one
quarter of the usual daily recommended dose [9].
Management
Patients who ingested less than 1.5 times their usual or the
maximum recommended thiopurine dose did not develop
symptoms and medical treatment or hospitalisation of such cases
(other than for psychiatric reasons) does not appear to be
indicated.
The Swiss product information for AZA and 6-MP does not
recommend the use of activated charcoal after overdose [9,10].
Other sources, however, recommend that activated charcoal be
used in overdose of these drugs [12]. When administered correctly,
activated charcoal is more effective, safer and more easily tolerated
than gastric lavage, which it has largely replaced in recent years
[14]. Due to the rarity of thiopurine overdose, it is not possible to
perform randomised controlled trials to determine the efficacy of
activated charcoal, and examination of case data such as ours is
therefore important. Interestingly, we found that activated
charcoal use in thiopurine overdose was more often associated
with asymptomatic courses than seen in untreated cases,
suggesting a benefit. On the basis of their chemical properties, a
good adsorption of thiopurines onto activated charcoal is to be
expected. AZA and 6-MP have molecular weights of 277 and 152
Dalton respectively, meaning that they are readily adsorbed into
the 10–20 A˚-sized charcoal pores [15]. The bioavailability of AZA
is high (88%), whereas that of 6-MP is low (16%, reduced to 11%
if ingested with food) and both reach their peak plasma
concentrations within 2 hours of ingestion [9,10]. It is therefore
reasonable to expect that activated charcoal is beneficial when
administered within 2 hours after overdose. However, activated
charcoal should be restricted to cases of definite overdose as its
administration is not without risk [16]. The fact that activated
charcoal was administered to children more often than to adults
possibly reflects their earlier presentation to emergency services
and the difficulty medical staff have in obtaining an accurate
account of the amount of drug ingested.
Prolonged hospitalisation for observation after thiopurine
overdose does not routinely seem warranted on the basis of the
data we present here. The maximum effect on the bone marrow is
usually seen after 9 to 14 days [9], so follow-up blood counts are
only meaningful when performed in this time period. However, no
cases of subsequent bone marrow or liver failure were reported in
this current large case series. This calls into question the need for
follow-up blood tests after acute overdose. As an alternative,
patients or caregivers could be instructed to represent themselves
to medical services if they begin to feel unwell or develop fever.
In patients normally taking AZA or 6-MP who have been
exposed to overdose, the decision about when these should be
restarted should take the current clinical situation (in particular
blood counts and liver function tests), the underlying disease
activity and the relatively short half-lives of the compounds into
consideration. The case of a single 50-fold AZA overdose reported
by Carney showed a second leukopenic episode when therapy was
reintroduced one week after overdose, so careful follow-up after
reintroduction of thiopurines after very large overdoses seems
prudent.
Limitations
It is likely that our data did not capture all cases of overdose
which occurred in the referral population. Our data are also
incomplete, which is the nature of retrospective studies using
poison centre data [17]. Unfortunately, a number of cases were
lost to follow-up after the initial contact, despite repeated efforts by
the STIC to contact the treating physicians in the days after
presentation. In some cases follow-up took place sooner than 10
days after overdose which is when bone marrow suppression after
ingestion of a thiopurine might be expected. A further limitation is
the lack of data regarding thiopurine blood or plasma concentra-
tions which would have allowed conclusions regarding pharma-
cokinetic-pharmacodynamic relationships and the effect of decon-
tamination on drug absorption to be drawn. However, such data
are not available as drug and metabolite concentrations for
thiopurines are not routinely measured.
In conclusion, acute thiopurine overdose occurred commonly in
the context of suicide attempt among adults and accidental
poisoning in the home among children. The acute overdoses were
well tolerated. In contrast, overdose over two or more consecutive
days, even if of modest size, was associated with abdominal
symptoms and liver function test and blood count abnormalities.
Gastrointestinal decontamination with activated charcoal ap-
peared to reduce symptom development after acute overdose
Acute Thiopurine Overdose
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and so should always be considered in cases presenting to
emergency services within 2 hours. Thiopurine overdose patterns,
outcomes and management require continued study and clinical
toxicologists, clinical pharmacologists and treating physicians
should be encouraged to actively seek follow-up data on the cases
with which they are involved.
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